Our top pick for
NeuroMetrix, Inc is a medical instruments & supplies business based in the US. NeuroMetrix shares (NURO) are listed on the NASDAQ and all prices are listed in US Dollars. NeuroMetrix employs 20 staff and has a trailing 12-month revenue of around USD$7.4 million.
|52-week range||USD$0.812 - USD$5.78|
|50-day moving average||USD$4.0765|
|200-day moving average||USD$2.529|
|Wall St. target price||USD$50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.395|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$7.4 million|
|Gross profit TTM||USD$5.2 million|
|Return on assets TTM||-14.65%|
|Return on equity TTM||-53.8%|
|Market capitalisation||USD$13.4 million|
TTM: trailing 12 months
There are currently 14,833 NeuroMetrix shares held short by investors – that's known as NeuroMetrix's "short interest". This figure is 42.7% down from 25,890 last month.
There are a few different ways that this level of interest in shorting NeuroMetrix shares can be evaluated.
NeuroMetrix's "short interest ratio" (SIR) is the quantity of NeuroMetrix shares currently shorted divided by the average quantity of NeuroMetrix shares traded daily (recently around 494433.33333333). NeuroMetrix's SIR currently stands at 0.03. In other words for every 100,000 NeuroMetrix shares traded daily on the market, roughly 30 shares are currently held short.
However NeuroMetrix's short interest can also be evaluated against the total number of NeuroMetrix shares, or, against the total number of tradable NeuroMetrix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeuroMetrix's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NeuroMetrix shares in existence, roughly 0 shares are currently held short) or 0.0039% of the tradable shares (for every 100,000 tradable NeuroMetrix shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NeuroMetrix.
Find out more about how you can short NeuroMetrix stock.
We're not expecting NeuroMetrix to pay a dividend over the next 12 months.
NeuroMetrix's shares were split on a 1:10 basis on 19 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuroMetrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for NeuroMetrix shares which in turn could have impacted NeuroMetrix's share price.
Over the last 12 months, NeuroMetrix's shares have ranged in value from as little as $0.812 up to $5.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuroMetrix's is 2.9685. This would suggest that NeuroMetrix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.